Can-Fite BioPharma, Ltd., a biotechnology company, develops drugs for the treatment of cancer and autoimmune inflammatory diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis; and has completed Phase II study for the treatment of rheumatoid arthritis and glaucoma, as well as completed Phase III study for the treatment of dry eye and Phase I study for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of hepatocellular carcinoma; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company was founded in 2000 and is based in Petach Tikva, Israel.